Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Degenhardt, Tom; Fasching, Peter A.; Lueftner, Diana et al.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrantTRIALS. Bd. 24. H. 1. 2023
Bennink, Herjan J. T. Coelingh; Schultz, Iman J.; Schmidt, Marcus et al.
Progesterone from ovulatory menstrual cycles is an important cause of breast cancerBREAST CANCER RESEARCH. Bd. 25. H. 1. 2023
Heimes, Anne-Sophie; Riedel, Natali; Almstedt, Katrin et al.
Prognostic Impact of CD38-and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast CancerINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 24. H. 20. 2023
Fasching, Peter A.; Brucker, Cosima; Decker, Thomas et al.
Progression-free survival and patient-reported outcomes in HR+, HER2-ABC patients treated with first-line ribociclib plus endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNACANCER RESEARCH. Bd. 83. H. 5. 2023
Bossart, M.; Plett, H.; Kraemer, B. et al.
Psychological distress and its influencing factors in survivors of malignant ovarian germ cell and sex-cord stromal tumors & mdash;an analysis of the AGO-CORSET T databaseONKOLOGIE. 2023
Theis, S.; Baumgartner, S. J.; Janka, H. et al.
Quality of life in menopausal women in the workplace - a systematic reviewCLIMACTERIC. Bd. 26. H. 2. 2023 S. 80-87
Decker, Thomas; Brucker, Cosima; Engel, Anne et al.
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNAJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Krajnak, Slavomir; Krajnakova, Jana; Anic, Katharina et al.
Real-world experience of metronomic chemotherapy in metastatic breast cancer: results of a retrospective unicenter studyBREAST CARE. 2023
Jackisch, Christian; Brucker, Cosima; Decker, Thomas et al.
RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib plus endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2-ABCCANCER RESEARCH. Bd. 83. H. 5. 2023
Harbeck, N.; Fasching, P. A.; Wuerstlein, R. et al.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HRD HER2L metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trialANNALS OF ONCOLOGY. Bd. 34. H. 8. 2023 S. 660-669